Jakafi access in India: the CDSCO named-patient pathway
How patients in the Republic of India legally obtain Jakafi (ruxolitinib) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.
Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.
Ask about Jakafi in India
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
Quick orientation
Patients in India access Jakafi (ruxolitinib) for intermediate or high-risk myelofibrosis, polycythaemia vera with inadequate response to or intolerance of hydroxyurea, and steroid-refractory acute or chronic graft-versus-host disease under the FDA label through the CDSCO named-patient pathway, a Central Drugs Standard Control Organisation-administered mechanism that allows an Indian-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and how to get a written quote.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Reserved for you.
How Jakafi reaches patients in India
Jakafi (ruxolitinib, oral JAK1 and JAK2 inhibitor, FDA-approved 2011 for intermediate or high-risk myelofibrosis, 2014 for polycythaemia vera with inadequate response to or intolerance of hydroxyurea, 2019 for steroid-refractory acute graft-versus-host disease, and 2021 for steroid-refractory chronic graft-versus-host disease in patients 12 years and older; marketed by Incyte) is registered in India through Novartis (the ex-US licensee for ruxolitinib) and appears on the CDSCO SUGAM database for selected presentations. Where the prescribed dose strength, indication, or paediatric cGVHD dosing is not locally stocked, Indian patients access Jakafi via Form 12-A personal-use import under Rules 36 and 36A of the Drugs and Cosmetics Rules 1945; the Form 12-B permit issues within one to two working days per cdsco.gov.in/consumer/Drugs-for-Personal-Use. Hospital-led imports use CT Form-16 under the New Drugs and Clinical Trials Rules 2019, particularly for BMT-unit administration in steroid-refractory cGVHD. The Jakafi-specific clinical justification must document the indication and disease-specific criteria: for MF, DIPSS or DIPSS-plus risk score and platelet-based starting dose (5 mg, 10 mg, 15 mg, 20 mg BID); for PV, intolerance or inadequate response to hydroxyurea per the FDA label; for steroid-refractory aGVHD or cGVHD, the steroid-refractoriness definition and prior systemic therapy lines. CBC surveillance schedule per the FDA label is referenced in the supporting medical report.
Where Jakafi is dispensed in India
Jakafi is an oral chronic therapy administered in haematology and bone marrow transplant outpatient settings with serial CBC surveillance.
What Jakafi costs in India
Medicine price: quote on request. You get a written quote for your case before you commit. Source: Drugs@FDA at accessdata.fda.gov/scripts/cder/daf and Incyte published pricing. NPPA at nppaindia.nic.in has not published a DPCO ceiling for ruxolitinib as of 2026-05-31.
Funding and access barriers for Jakafi in India
MF and PV affect predominantly older adults with annual incidence approximately 1 per 100,000 each. Public-sector funding: RAN at mohfw.gov.in provides BPL assistance at designated super-specialty hospitals up to a defined ceiling; HMCPF earmarks for cancer treatment at designated RCCs. Ayushman Bharat PM-JAY does not consistently list ruxolitinib by name. State schemes (Tamil Nadu CMCHIS, Kerala KASP, Karnataka, Andhra Aarogyasri) include selected myeloproliferative-neoplasm packages with state-specific drug lists. Private insurance: standalone health insurers and general insurers' health portfolios increasingly cover ruxolitinib on higher-tier individual and corporate group policies with prior authorisation and step-therapy documentation (hydroxyurea failure or intolerance for PV; risk-stratification documentation for MF; corticosteroid-refractory documentation for GVHD). Novartis India operates the Jakavi Patient Support Programme through registered haematology centres; eligibility is means-tested and includes co-pay assistance. For steroid-refractory cGVHD, the FDA label dose (10 mg BID) often runs concurrent with BMT-unit transplantation costs, which Ayushman Bharat and state schemes partially cover. Crowdfunding (Ketto, Milaap, ImpactGuru) is a documented complementary route for sustained ruxolitinib funding.
Recent regulatory and access news for Jakafi
FDA-approved (June 2023) ruxolitinib cream for vitiligo in patients 12 years and older (Opzelura) is a separate product from oral Jakafi but shares the active. FDA continues post-marketing surveillance on long-term safety, particularly serious infections and second primary malignancies, with periodic labelling updates published at accessdata.fda.gov/scripts/cder/daf. EMA has retained the Jakavi label across MF, PV, GVHD, and chronic GVHD; the European public assessment reports are at ema.europa.eu/medicines. CDSCO Notifications at cdsco.gov.in/Notifications have not issued a ruxolitinib-specific bulletin over the last 12 months as of 2026-05-31. NPPA has not added ruxolitinib to a DPCO ceiling list.
Where Reserve Meds fits in Jakafi cases
Reserve Meds is a US-based digital health company. We do not replace your treating physician, we do not replace CDSCO, and we do not replace your dispensing pharmacy. For Jakafi specifically, we orchestrate supply through a US-licensed pharmaceutical wholesale partner, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into India, and give you one point of contact through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.
Operationally, a typical Jakafi case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the CDSCO application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the case coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.
Rule 36 personal import applies.
Next step
If your Indian physician has prescribed Jakafi and you are weighing the cross-border route, the next step is a short intake. We reply within one business day, then send a documentation checklist to your doctor.
Reserved for you.